Savara: Trial Successful, But I'm Only Half Convinced [Seeking Alpha]
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Seeking Alpha
Summary Savara's Molgramostim, a GM-CSF therapy, succeeded in a phase 3 trial for treating aPAP, a rare autoimmune lung condition, after a previous failure. The current standard treatment, WLL, is effective but complex, costly, and invasive, making GM-CSF a potentially preferable alternative despite its high price. Despite meeting primary endpoints in IMPALA-2, concerns remain about endpoint changes and high costs, making the investment risky. With a cash runway into 2026, Savara faces challenges convincing the market and FDA of Molgramostim's superiority. Hiroshi Watanabe Savara Inc. ( NASDAQ: SVRA ) is developing Molgramostim, "a non-glycosylated form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)," in a nebulizer formulation. The target indication is a rare disease called Autoimmune Pulmonary Alveolar Proteinosis (aPAP), a form of PAP. I covered SVRA in , when it did not have data, and then again in , when it had already failed its phase
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.MarketBeat
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 [YahooYahoo
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024Business Wire
- Savara Announces New Employment Inducement GrantBusiness Wire
- Savara to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
SVRA
Earnings
- 8/12/24 - Miss
SVRA
Sec Filings
- 8/14/24 - Form SC
- 8/12/24 - Form 10-Q
- 7/26/24 - Form S-8
- SVRA's page on the SEC website